HK Stock Market Move | EVEREST MED (01952) rises over 10%; U.S. stock Moderna surges 14% in a single day; the company accelerates its global mRNA layout.

EVEREST MED (01952) rose over 10%, up 10.07% as of press time, at HK$32.58, with a turnover of HK$88.0284 million. On the news front, U.S. vaccine stocks surged broadly last Friday, with Moderna jumping over 14%, hitting a new high since January 2022. According to reports, the U.S. National Institutes of Health (NIH) is preparing to launch a nationwide cancer vaccine research and development program, which will reference the rapid development model of COVID-19 vaccines. Through government collaboration with pharmaceutical companies and research institutions, it aims to accelerate vaccine R&D and clinical trials, with an expected official launch in December this year. In August this year, Moderna's personalized mRNA cancer vaccine in Phase III clinical trials, jointly developed with Merck, achieved positive results, demonstrating the feasibility of mRNA in tumor treatment and prompting global capital markets to reassess the value of this track. It is worth noting that EVEREST MED recently announced the appointment of Dr. Lakshmi Srinivasan as Senior Vice President and Head of Translational Medicine, and Dr. Brandon Coder as Vice President of Translational Science and Early Research. Both new executives possess deep industry experience and professional backgrounds, having previously led cancer vaccine R&D at globally leading biopharmaceutical companies such as Moderna, with comprehensive hands-on experience spanning from early discovery to clinical translation and clinical development. This significant talent acquisition is a key move by EVEREST MED to accelerate its global mRNA strategy.